NightHawk Biosciences’ Scorpion subsidiary hosted the grand opening of its San Antonio facility on October 21.
 
David Halverson, president of Scorpion, commented, “We are pleased with the recent FDA feedback regarding our design, operational strategy, and environmental controls relevant to clinical and commercial manufacturing at our San Antonio facility. In addition, the planning for our new facility in Manhattan, Kansas continues to progress. These two facilities, once fully operational, will provide Scorpion with substantial biomanufacturing capabilities to accommodate future worldwide demand for biologic manufacturing.”
 
The global pharmaceutical CDMO market is projected to reach $171 billion by 2026 from $120 billion in 20211. The industry currently suffers from a significant lack of capacity, resulting in meaningful delays and escalating costs.
 
The company also reports its Scorpion subsidiary recently entered into a commercial contract to provide contract development and manufacturing services for a biopharmaceutical company to support development of their Phase 3 asset.
 
Jeff Wolf, CEO of Nighthawk, further noted, “Our Scorpion San Antonio facility…represents an important milestone for the Company as we continue to execute on our strategy to develop a fully-integrated ecosystem that is designed to enable more rapid delivery of medical innovations with increased quality and efficiency.”